We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DaVita Inc. (DVA - Free Report) has been gaining from strong execution across its Integrated Kidney Care (“IKC”) platform, improving treatment volumes and investments in technology and clinical innovation. The optimism is driven by solid first-quarter 2026 results and higher full-year guidance. However, intense competition, commercial payer-mix pressures and regulatory and macroeconomic uncertainty remain key concerns.
Year to date, this Zacks Rank #3 (Hold) stock has rallied 55.8%, outperforming the industry’s 19.8% growth and the S&P 500’s 14.5% gain.
The renowned global comprehensive kidney care provider has a market capitalization of $11.28 billion. The company projects 26.5% growth over the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 0.14%.
Image Source: Zacks Investment Research
DVA’s Prospect Drivers
IKC Offers a Scalable Earnings Growth Opportunity: IKC is emerging as a meaningful avenue for DaVita to diversify growth beyond traditional dialysis operations. Management said IKC generated $40 million of adjusted operating income above expectations in the second quarter, although timing of revenue recognition was a major factor.
The company sees significant growth opportunities through improved economics and an expansion in the number of people and dollars under management. Management also expects to add more contracts with Medicare Advantage plans. As the model matures, closer coordination among nephrologists, clinics and DaVita could enhance care management and drive a growing contribution to operating earnings.
Improving Treatment Economics Could Support Margin Expansion: DaVita is seeing signs of moderating per-treatment cost pressures as treatment volumes improve.Patient care cost per treatment declined approximately $3 sequentially in the second quarter, primarily because higher treatment volumes created operating leverage on labor and other fixed costs, while lower phosphate-binder expenses provided an additional benefit.
Although year-to-date patient care costs remained above the company’s full-year target, management expects year-over-year cost growth to decelerate in the second half as phosphate-binder expenses decline and facility-maintenance growth moderates. If treatment volumes continue improving, greater absorption of fixed operating expenses could provide incremental earnings leverage even without significant increases in revenue per treatment.
Stronger Formulary Adoption Can Improve Treatment Quality and Utilization: DaVita’s broad phosphate-binder formulary is generating an important clinical and operational benefit following the transition of these medications into the Medicare dialysis bundle. Management said the number of patients relying on less-effective over-the-counter alternatives such as TUMS has fallen by more than 50%, allowing more patients to receive clinically preferred therapies.
Better phosphate management can reduce risks associated with cardiovascular complications and bone fractures, supporting improved patient outcomes over time. The development also demonstrates DaVita’s ability to implement major treatment-policy changes across its network. As the company continues optimizing bundled-care protocols, stronger treatment adherence and clinical consistency could support its broader quality-of-care strategy.
Key Risks
Revenue per Treatment Faces Persistent Commercial-Mix Pressure: DaVita’s biggest near-term earnings constraint may come from declining revenue per treatment rather than treatment volumes. Revenue per treatment (RPT) declined approximately $2 sequentially during the second quarter, primarily because of lower commercial mix following the expiration of ACA subsidies and reduced phosphate-binder revenues.
Management expects full-year RPT growth of only 1-2%, implying slightly negative year-over-year RPT growth in the second half. The company estimates that the commercial-mix shift could represent a roughly $70 million impact in 2027, as new patient admissions increasingly arrive with lower commercial coverage. This creates a structural offset to volume growth and limits the earnings benefit from improving treatment volumes.
Elevated Corporate and Operating Expenses Could Limit Volume Leverage: Despite treatment growth, DaVita has not yet translated the improvement fully into U.S. dialysis operating-income growth. Management noted that U.S. dialysis operating income was relatively flat year over year in the second quarter, with G&A growth of roughly 10% acting as one of the principal offsets. This is particularly important as treatment volumes increase while the company faces higher administrative expenses.
If G&A remains elevated, incremental treatment volumes may generate less operating leverage than investors expect. Management needs continued discipline around corporate costs to ensure that improving clinical outcomes and treatment volumes translate into stronger segment profitability rather than being absorbed by higher overhead.
Limited Acquisition Opportunities Could Constrain External Growth: DaVita’s ability to accelerate growth through acquisitions appears increasingly limited because the U.S. dialysis market has become highly consolidated.
Management said there are still smaller clinic opportunities available, but characterized the market as having relatively few acquisition targets. Consequently, future domestic expansion is expected to rely more heavily on de novo clinics as industry treatment volumes improve. This shifts the growth profile toward internally developed capacity, which generally requires more time to build patient density and establish operating maturity.
While the strategy can support long-term expansion, the scarcity of attractive acquisition opportunities reduces DaVita’s ability to rapidly increase market share through inorganic growth and places greater importance on execution of its organic expansion pipeline.
DaVita is witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share has remained unchanged at $14.57.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $3.53 billion, indicating a 3.2% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $3.78 per share, implying 50.6% year-over-year growth.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Outset Medical (OM - Free Report) and Merit Medical Systems (MMSI - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.9%.
Outset Medical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 loss per share of 80 cents, which missed the Zacks Consensus Estimate by 26.9%. Revenues of $32 million surpassed the Zacks Consensus Estimate by 9.8%.
OM has an estimated earnings growth rate of 28.4% for 2027. OM’s earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 31.63%.
Merit Medical Systems, currently carrying a Zacks Rank of 2, reported a second-quarter 2026 adjusted EPS of $1.19, which surpassed the Zacks Consensus Estimate by 24%. Revenues of $419 million beat the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 14.10%.
View the Zacks #1 Rank List
Image: Bigstock
Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
Key Takeaways
DaVita Inc. (DVA - Free Report) has been gaining from strong execution across its Integrated Kidney Care (“IKC”) platform, improving treatment volumes and investments in technology and clinical innovation. The optimism is driven by solid first-quarter 2026 results and higher full-year guidance. However, intense competition, commercial payer-mix pressures and regulatory and macroeconomic uncertainty remain key concerns.
Year to date, this Zacks Rank #3 (Hold) stock has rallied 55.8%, outperforming the industry’s 19.8% growth and the S&P 500’s 14.5% gain.
The renowned global comprehensive kidney care provider has a market capitalization of $11.28 billion. The company projects 26.5% growth over the next five years and expects to maintain its strong performance going forward. DaVita’s earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, the average surprise being 0.14%.
Image Source: Zacks Investment Research
DVA’s Prospect Drivers
IKC Offers a Scalable Earnings Growth Opportunity: IKC is emerging as a meaningful avenue for DaVita to diversify growth beyond traditional dialysis operations. Management said IKC generated $40 million of adjusted operating income above expectations in the second quarter, although timing of revenue recognition was a major factor.
The company sees significant growth opportunities through improved economics and an expansion in the number of people and dollars under management. Management also expects to add more contracts with Medicare Advantage plans. As the model matures, closer coordination among nephrologists, clinics and DaVita could enhance care management and drive a growing contribution to operating earnings.
Improving Treatment Economics Could Support Margin Expansion: DaVita is seeing signs of moderating per-treatment cost pressures as treatment volumes improve.Patient care cost per treatment declined approximately $3 sequentially in the second quarter, primarily because higher treatment volumes created operating leverage on labor and other fixed costs, while lower phosphate-binder expenses provided an additional benefit.
Although year-to-date patient care costs remained above the company’s full-year target, management expects year-over-year cost growth to decelerate in the second half as phosphate-binder expenses decline and facility-maintenance growth moderates. If treatment volumes continue improving, greater absorption of fixed operating expenses could provide incremental earnings leverage even without significant increases in revenue per treatment.
Stronger Formulary Adoption Can Improve Treatment Quality and Utilization: DaVita’s broad phosphate-binder formulary is generating an important clinical and operational benefit following the transition of these medications into the Medicare dialysis bundle. Management said the number of patients relying on less-effective over-the-counter alternatives such as TUMS has fallen by more than 50%, allowing more patients to receive clinically preferred therapies.
Better phosphate management can reduce risks associated with cardiovascular complications and bone fractures, supporting improved patient outcomes over time. The development also demonstrates DaVita’s ability to implement major treatment-policy changes across its network. As the company continues optimizing bundled-care protocols, stronger treatment adherence and clinical consistency could support its broader quality-of-care strategy.
Key Risks
Revenue per Treatment Faces Persistent Commercial-Mix Pressure: DaVita’s biggest near-term earnings constraint may come from declining revenue per treatment rather than treatment volumes. Revenue per treatment (RPT) declined approximately $2 sequentially during the second quarter, primarily because of lower commercial mix following the expiration of ACA subsidies and reduced phosphate-binder revenues.
Management expects full-year RPT growth of only 1-2%, implying slightly negative year-over-year RPT growth in the second half. The company estimates that the commercial-mix shift could represent a roughly $70 million impact in 2027, as new patient admissions increasingly arrive with lower commercial coverage. This creates a structural offset to volume growth and limits the earnings benefit from improving treatment volumes.
Elevated Corporate and Operating Expenses Could Limit Volume Leverage: Despite treatment growth, DaVita has not yet translated the improvement fully into U.S. dialysis operating-income growth. Management noted that U.S. dialysis operating income was relatively flat year over year in the second quarter, with G&A growth of roughly 10% acting as one of the principal offsets. This is particularly important as treatment volumes increase while the company faces higher administrative expenses.
If G&A remains elevated, incremental treatment volumes may generate less operating leverage than investors expect. Management needs continued discipline around corporate costs to ensure that improving clinical outcomes and treatment volumes translate into stronger segment profitability rather than being absorbed by higher overhead.
Limited Acquisition Opportunities Could Constrain External Growth: DaVita’s ability to accelerate growth through acquisitions appears increasingly limited because the U.S. dialysis market has become highly consolidated.
Management said there are still smaller clinic opportunities available, but characterized the market as having relatively few acquisition targets. Consequently, future domestic expansion is expected to rely more heavily on de novo clinics as industry treatment volumes improve. This shifts the growth profile toward internally developed capacity, which generally requires more time to build patient density and establish operating maturity.
While the strategy can support long-term expansion, the scarcity of attractive acquisition opportunities reduces DaVita’s ability to rapidly increase market share through inorganic growth and places greater importance on execution of its organic expansion pipeline.
DaVita Inc. Price
DaVita Inc. price | DaVita Inc. Quote
Estimate Trend
DaVita is witnessing a stable estimate revision trend for 2026. Over the past 30 days, the Zacks Consensus Estimate for earnings per share has remained unchanged at $14.57.
The Zacks Consensus Estimate for the company’s third-quarter 2026 revenues is pegged at $3.53 billion, indicating a 3.2% uptick from the year-ago quarter’s reported number. The consensus mark for earnings is pegged at $3.78 per share, implying 50.6% year-over-year growth.
Stocks to Consider
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , Outset Medical (OM - Free Report) and Merit Medical Systems (MMSI - Free Report) .
Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 27.9%.
Outset Medical, carrying a Zacks Rank #2 at present, reported second-quarter 2026 loss per share of 80 cents, which missed the Zacks Consensus Estimate by 26.9%. Revenues of $32 million surpassed the Zacks Consensus Estimate by 9.8%.
OM has an estimated earnings growth rate of 28.4% for 2027. OM’s earnings missed estimates in each of the trailing four quarters, with the average negative surprise being 31.63%.
Merit Medical Systems, currently carrying a Zacks Rank of 2, reported a second-quarter 2026 adjusted EPS of $1.19, which surpassed the Zacks Consensus Estimate by 24%. Revenues of $419 million beat the Zacks Consensus Estimate by 3.5%.
MMSI has an estimated long-term earnings growth rate of 10.4%. The company’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 14.10%.